Related Experiment Videos
Estramustine-binding protein in malignant glioma in rat
A E Karlsson1, P Björk, A T Bergenheim
1Department of Oncology, Umeti University, Umeå, Sweden.
Journal of Neuro-Oncology
|December 29, 2000
Summary
Estramustine-binding protein (EMBP) is expressed in rat glioma, similar to prostate cancer. This finding supports the use of rat glioma models for studying estramustine
Area of Science:
- Biochemistry
- Oncology
- Molecular Biology
Background:
- Estramustine is a chemotherapy drug used for prostate cancer.
- Estramustine binds to estramustine-binding protein (EMBP) in the prostate.
- EMBP expression and estramustine binding are also found in malignant glioma, correlating with poor prognosis in astrocytoma.
Purpose of the Study:
- To confirm the expression of all three polypeptide components of EMBP in an orthotopic rat glioma model.
- To characterize the binding of estramustine to EMBP in this model.
- To validate the rat glioma model for further estramustine research.
Main Methods:
- Nested reverse transcriptase PCR and Western blot were used to confirm EMBP polypeptide expression.
- Scatchard plot analysis was employed to determine estramustine binding characteristics.
- An orthotopic rat glioma model (BT4C) was utilized.
Main Results:
- All three EMBP polypeptide components (8, 10, and 12 kDa) were confirmed in the rat glioma model.
- Estramustine demonstrated specific binding to EMBP, with binding characteristics similar to those in prostatic EMBP.
- Binding affinity (Kd) and total binding sites were quantified for male and female rats.
Conclusions:
- The expression of EMBP in rat glioma is confirmed, validating its use as a model system.
- The binding characteristics of estramustine to EMBP in glioma are similar to those in prostate cancer.
- Further research on EMBP's role in estramustine treatment and its prognostic value is warranted.